REG-Arix Bioscience PLC Aura Biosciences prices Nasdaq IPO

Arix BioscienceAnnouncement

29/10/2021 07:05

============

   Arix Bioscience PLC (ARIX)
   Aura Biosciences prices Nasdaq IPO

   29-Oct-2021 / 07:00 GMT/BST
   Dissemination of a Regulatory Announcement, transmitted by EQS Group.
   The issuer is solely responsible for the content of this announcement.

   ══════════════════════════════════════════════════════════════════════════

    

    

                              Arix Bioscience plc

                                        

                                     Update

                       Aura Biosciences prices Nasdaq IPO

                                        

    

   LONDON, 29 October 2021: Arix Bioscience plc (LSE: ARIX, "Arix"), a global
   venture capital company focused on investing in and building  breakthrough
   biotech  companies,  today   notes  that  its   portfolio  company,   Aura
   Biosciences, Inc.,  ("Aura"), has  announced the  pricing of  its  initial
   public offering of 5,400,000 shares of  common stock at a public  offering
   price of $14.00 per share for  aggregate gross proceeds of $75.6  million.
   In addition, Aura has granted the  underwriters an option for a period  of
   30 days to purchase up to  810,000 additional shares of common stock.  All
   of the shares are being offered  by Aura. Aura's common stock is  expected
   to begin trading on the Nasdaq Global Market on 29 October 2021 under  the
   ticker symbol "AURA".

    

   The IPO resulted  in a £3.7  million 1  (2.8p per  share) increase in  the
   value of  Arix's existing  holding  in Aura,  which  was valued  at  £11.7
   million at 30 June 2021 2 .

   A registration statement relating to these securities has been filed  with
   and declared effective  by the  U.S. Securities  and Exchange  Commission.
   This announcement does not constitute an offer to sell or the solicitation
   of an  offer  to  buy  securities, and  shall  not  constitute  an  offer,
   solicitation or sale in any jurisdiction in which such offer, solicitation
   or sale would be unlawful prior to registration or qualification under the
   securities laws of that jurisdiction. Any offers, solicitations or  offers
   to buy, or any  sales of securities  will be made  in accordance with  the
   registration requirements of the Securities Act of 1933, as amended.

                                      ENDS 

    

   Enquiries

   For more information on Arix, please contact:

    

   Arix Bioscience plc

   +44 (0)20 7290 1050

   ir@arixbioscience.com

    

   Optimum Strategic Communications

   Mary Clark, Manel Mateus

   +44 (0)20 8078 4357

   optimum.arix@optimumcomms.com

    

   About Arix Bioscience plc

   Arix Bioscience plc is a global venture capital company focused on
   investing in and building breakthrough biotech companies around cutting
   edge advances in life sciences. We collaborate with exceptional
   entrepreneurs and provide the capital, expertise and global networks to
   help accelerate their ideas into important new treatments for patients. As
   a listed company, we are able to bring this exciting growth phase of our
   industry to a broader range of investors.

    

   About Aura Biosciences

   Aura Biosciences, Inc. is a clinical-stage oncology company developing a
   novel technology platform based on virus-like drug conjugates (VDCs) to
   target and destroy cancer cells selectively while activating the immune
   system to create long lasting anti-tumor immunity. The VDC technology
   platform is based on the discoveries of NIH Distinguished Investigator Dr.
   John Schiller of the Center for Cancer Research at the National Cancer
   Institute (NCI). The company has the goal of developing this technology in
   multiple cancer indications with an initial focus on primary choroidal
   melanoma, a rare disease for which there are no approved drugs. Aura's
   lead product candidate belzupacap sarotalocan (AU-011) is currently in
   Phase 2 development for the first line treatment of primary choroidal
   melanoma, a vision and life-threatening form of eye cancer where standard
   of care radioactive treatments leave patients with major vision loss and
   severe comorbidities. AU-011 was well tolerated in a Phase 1b/2 trial,
   demonstrating high rates of tumor control and vision preservation. Future
   pipeline applications for Aura's technology include additional ocular
   oncology indications like choroidal metastases and solid tumor indications
   like non-muscle invasive bladder cancer. Aura is headquartered in
   Cambridge, MA. For more information, visit www.aurabiosciences.com.

    

   [] At exchange rate on 28 October 2021

    2  At exchange rate on 30 June 2021

    

   ══════════════════════════════════════════════════════════════════════════

   ISIN:           GB00BD045071
   Category Code:  MSCH
   TIDM:           ARIX
   LEI Code:       213800OVT3AHQCXNIX43
   OAM Categories: 3.1. Additional regulated information required to be
                   disclosed under the laws of a Member State
   Sequence No.:   125512
   EQS News ID:    1244635


    
   End of Announcement EQS News Service

   ══════════════════════════════════════════════════════════════════════════

    1 fncls.ssp?fn=show_t_gif&application_id=1244635&application_name=news&site_id=reuters8

References

   Visible links


============